source
- Estuary sails into kidney disease space with $103M for gene therapiesEstuary Biotherapeutics is seeking to address the root cause of autosomal dominant polycystic kidney disease with two gene therapy programs based on science from Yale.BioSpace · 5d ago↗ source
- OrbiMed raises two new life sciences funds worth $3B with one aiming for AsiaThe sixth cycle of OrbiMed’s Asia Partners fund included one with more than $1 billion earmarked for life science companies based on the Eastern continent.BioSpace · 5d ago↗ source
- FDA issues early alert for Edwards Lifesciences’ mitral valve delivery system after reported death, injuryThe FDA has issued an early alert for certain delivery systems used with Edwards Lifesciences’ SAPIEN M3 transcatheter mitral valve replacement system amid serious safety concerns.